Application of pimozide as African swine fever virus inhibitor

By studying the diphendipiperidine substance pimozide, the problem of lack of effective drugs for African swine fever treatment was solved. Pimozide showed strong anti-ASFV activity in vitro and had low cytotoxicity, which promoted African swine fever Development of new drugs.

CN119015423AActive Publication Date: 2024-11-26CHINA INST OF VETERINARY DRUG CONTROL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411161731.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-26
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

There is currently no safe and effective vaccine for the treatment of African swine fever, and there is insufficient drug development for the African swine fever virus.

Method used

Research and use of diphenylpiperidine-based pimozide as a potential anti-African swine fever drug to verify its effect on inhibiting ASFV by in vitro models, and develop compositions containing pimozide for prevention or treatment of Africa Swine fever.

Benefits of technology

Pimozide showed strong anti-ASFV activity in vitro, had low cytotoxicity, and had significant inhibitory effect on ASFV at effective concentrations, which had huge potential value in the development of new drugs for the prevention and treatment of African swine fever.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure HDA0005007610170000011
    Figure HDA0005007610170000011
Patent Text Reader

Abstract

The invention relates to application of a diphenylbutyl piperidine medicine in prevention or treatment of African swine fever, in particular to application of pimozide in prevention or treatment of diseases related to African swine fever and complications thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to application of a diphenylbutazone substance in treating African swine fever. Background Art

[0002] African swine fever (ASF) is a highly contagious disease caused by African swine fever virus (ASFV). Highly virulent strains can cause acute death in domestic pigs, moderately virulent strains can cause acute to subacute symptoms in domestic pigs, and weakly virulent strains can cause mild or even unnoticeable symptoms in domestic pigs. ASFV was first discovered in Kenya, Africa in 1921, and was introduced to Portugal in Europe in 1957. It was introduced to Cuba in South America from 1971 to 1980. Subsequently, other American countries reported ASF outbreaks, and it was introduced to Georgia in Asia in 2007 and China in 2018. ASFV has been around for a hundred years since its discovery, causing a devastating blow to the global pig industry. There is currently no safe and effective vaccine. Therefore, it is particularly important to develop drugs against ASFV.

[0003] Pimozide is a dopamine receptor antagonist, a D2 receptor antagonist, a STAT3 / STAT5 inhibitor, a diphenylbutylpiperidine derivative and a dopamine antagonist with antipsychotic properties. Pimozide molecular formula: C 18 H 29 F2N3O, relative molecular mass: 461.55. The chemical structure is as follows.

[0004]

[0005] Pimozide selectively inhibits type 2 dopamine receptors in the central nervous system (CNS), thereby inhibiting dopamine neurotransmission and reducing the occurrence of motor vocal tics and delusions. Pimozide has a high affinity for α1-adrenoceptor, with a Ki value of 39nM. In addition, Pimozide antagonizes α-adrenergic receptors and 5-HT 2 receptors. Pimozide has a high affinity for 5-HT 7 receptors (Ki = 0.5nM). Pimozide reduces STAT5 tyrosine phosphorylation and can be used to treat mental disorders, antipsychotic drugs, and can also inhibit the proliferation of various cancer cells, such as colorectal cancer, human osteosarcoma and hepatocellular carcinoma.

[0006] There are currently no research reports on the anti-African swine fever virus effect of pimozide, nor are there any related patents published. Summary of the invention

[0007] In response to the above technical problems, the present application tested the therapeutic effect of the diphenylpiperidine substance pimozide in an in vitro model.

[0008] Specifically, the technical solution of this application is as follows:

[0009] 1. Use of diphenylbutazone-type substances in the preparation of drugs or preparations for preventing or treating African swine fever.

[0010] 2. The use as described in item 1, wherein the diphenylpiperidine-type substance is one or more of pimozide, fluspiride, fluphenazine and penfluridol.

[0011] 3. The use as described in item 1, wherein the diphenylbutyridine substance is pimozide.

[0012] 4. The use as described in item 3, wherein an effective dose of pimozide is administered to the subject, wherein the effective dose is 50 mg / kg-70 mg / kg

[0013] 5. A composition for preventing or treating African swine fever, comprising diphenylbutazone substances and pharmaceutically acceptable excipients, and preferably also comprising other pharmaceutically active ingredients.

[0014] 6. The composition as described in item 5, wherein the diphenylpiperidine-type substance is one or more of pimozide, fluspiride, fluphenazine and penfluridol.

[0015] 7. A composition according to claim 5, wherein the diphenylpiperidine substance is pimozide.

[0016] 8. The composition according to item 7, wherein the concentration of pimozide in the composition is 0.625-10 μM.

[0017] 9. The composition according to item 7, wherein the dosage of pimozide is 20 mg / kg-100 mg / kg.

[0018] The advantages of this application are:

[0019] 1. Pimozide has a strong inhibitory effect on ASFV in vitro and has significant anti-ASFV activity at a concentration of 1.19 μM, indicating that it has a highly effective anti-ASFV effect.

[0020] 2. Pimozide has a low cytotoxic effect. The half cytotoxic dose (CC50) in the in vitro cytotoxicity test is 83.75 μM. It shows a low cytotoxic effect when it is more than 40 times higher than the effective concentration. Normal use does not affect the proliferation of PAM cells.

[0021] 3. The raw materials of Pimozide are widely available, low-cost, safe and reliable, so it has great potential value in the development of new drugs for the prevention and treatment of African swine fever. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is a schematic diagram of the CCK-8 method for detecting the cytotoxicity of different concentrations of pimozide on PAM cells.

[0023] Figure 2 This is a schematic diagram of the effect of different concentrations of pimozide on ASFV proliferation in PAM cells measured by qPCR.

[0024] Figure 3A This is a schematic diagram of the effect of different concentrations of pimozide on ASFV titer in PAM cells measured using HAD50.

[0025] Figure 3B This is a schematic diagram of the effect of different concentrations of pimozide on rosette spots formed by ASFV proliferation in PAM cells measured by HAD50.

[0026] Figure 4 This is a schematic diagram of the effect of different concentrations of pimozide on different proliferation stages of ASFV in PAM cells measured by qPCR. DETAILED DESCRIPTION

[0027] The present application is described in detail below. Although the specific embodiments of the present application are shown below, it should be understood that the present application can be implemented in various forms and should not be limited by the embodiments described here. On the contrary, these embodiments are provided to enable a more thorough understanding of the present application and to fully convey the scope of the present application to those skilled in the art. The scope of protection of the present application shall be determined by the definition of the attached claims.

[0028] The present application relates to the use of diphenylbutazone substances in preventing or treating African swine fever.

[0029] As used herein, the term "treat," "treat," or "treating" means reversing, alleviating, inhibiting the progression of, or preventing the disease or condition to which such term applies, or one or more symptoms of such disease or condition.

[0030] The diphenylbutyridines described in this application are a new subtype of butyrophenones, which are formed by replacing the ketone side chain with 4-fluorophenylmethionine. Pimozide, fluspirin, fluspirin and penfluridol etc. belong to this class. The common feature of this class of drugs is long action time. For example, the single oral action time of pimozide is 24 hours, so it can be taken once a day. Another feature is that it is effective for both acute and chronic positive and negative symptoms of schizophrenia. They are both dopamine receptor blockers and calcium ion channel blockers. Other antipsychotic drugs do not have this effect, so they are unique. It is speculated that the reason why they are effective for the negative symptoms of schizophrenia may be related to this. Systematic research on central calcium ion blockers is said to provide more effective drugs for the negative symptoms of schizophrenia.

[0031] The present application also provides the use of diphenylbutazone substances in the preparation of drugs or preparations for preventing or treating African swine fever.

[0032] In some specific embodiments, the African swine fever is an infectious disease caused by the African swine fever virus, preferably an infectious disease caused by the African swine fever virus.

[0033] In some specific embodiments, the African swine fever is selected from the group consisting of high fever, loss of appetite or decreased appetite, whole body cramps, limb convulsions, fibrous thrombosis, conjunctivitis, mental depression, conjunctivitis, acute enteritis, purple spots or plaques, bran spots on the body; constipation, diarrhea, vomiting, tremors, lethargy, fluffy hair, hind limb paralysis, movement disorders, leukocytopenia, punctate hemorrhages in the kidneys, hemorrhages around lymph node sections; marbled lymph node sections; punctate hemorrhages on the surface of the spleen or wedge-shaped infarction areas on the edges, thrombotic necrosis of blood vessels; punctate hemorrhages in the heart, laryngeal bladder, and gallbladder; leukocytic anemia, decreased white blood cell count, decreased lymphocyte count, and the like.

[0034] In some embodiments, the African swine fever comprises weakness, chills, convulsions, and stunted growth in piglets.

[0035] The present application also provides a composition for preventing or treating African swine fever, which comprises a diphenylbutazone substance and a pharmaceutically acceptable excipient.

[0036] In some specific embodiments, the pharmaceutically acceptable excipients include diluents (e.g., starch, pregelatinized starch, dextrin, sucrose, lactose, mannitol, microcrystalline cellulose, etc.), absorbents (e.g., calcium sulfate, calcium hydrogen phosphate, light magnesium oxide, calcium carbonate, etc.), wetting agents (e.g., water, ethanol, etc.), binders (e.g., hydroxypropyl methylcellulose (HPMC), polyvidone (PVP), starch slurry, syrup, etc.), disintegrants (e.g., dry starch, sodium hydroxymethyl starch, low-substituted hydroxypropyl cellulose, effervescent disintegrants, cross-linked polyvinylpyrrolidone, etc.), lubricants (e.g., magnesium stearate, talc, hydrogenated vegetable oil, polyethylene glycol, micronized silica gel), colorants (e.g., titanium dioxide, sunset yellow, methylene blue, medicinal iron oxide red), coating materials (e.g., acrylic resin, hydroxypropyl methylcellulose, povidone, cellulose acetate, etc.), and the like.

[0037] In a preferred embodiment, the composition further comprises other pharmaceutically active ingredients.

[0038] In some specific embodiments, the other pharmaceutically active ingredients include non-steroidal anti-inflammatory drugs or glucocorticoids, such as aspirin, indomethacin, naproxen, naproxen, diclofenac, rofecoxib, methylprednisolone, beclomethasone dipropionate, prednisolone, hydrocortisone, etc.

[0039] In a specific embodiment, the concentration of the diphenylbutyridine substance in the composition is 0.625-10 μM. For example, it can be 0.625 μM, 0.65 μM, 0.675 μM, 0.7 μM, 0.75 μM, 0.775 μM, 0.8 μM, 0.825 μM, 0.85 μM, 0.875 μM, 0.9 μM, 0.925 μM, 0.95 μM, 0.975 μM, 1 μM, 1.5 μM, 2 μM, 2.5 μM, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM, 5.5 μM, 6 μM, 6.5 μM, 7 μM, 7.5 μM, 8 μM, 8.5 μM, 9 μM, 9.5 μM, 10 μM.

[0040] In a specific embodiment, the dosage of the diphenylbutyridine substance is 20mg / kg-100mg / kg. For example, the dosage of the diphenylbutyridine substance can be 20mg / kg, 25mg / kg, 30mg / kg, 35mg / kg, 40mg / kg, 45mg / kg, 50mg / kg, 55mg / kg, 60mg / kg, 65mg / kg, 70mg / kg, 75mg / kg, 80mg / kg, 85mg / kg, 90mg / kg, 95mg / kg, 100mg / kg, preferably 50mg / kg-70mg / kg

[0041] In the present application, the unit of mg / kg refers to the weight of the subject. For example, if the subject weighs 100 kg, then 50 mg / kg means that a dose of 50*100 mg of the substance is administered to the subject.

[0042] In a specific embodiment, the medicine or preparation provided in the present application further includes a pharmaceutically acceptable carrier.

[0043] Specifically, examples of the above-mentioned pharmaceutically acceptable carriers include binders, buffers, antioxidants, solubilizers, thickeners, lubricants, disintegrants, diluents, stabilizers, preservatives, colorants, flavoring agents, dissolution aids, emulsifiers, isotonic agents and the like.

[0044] In a specific embodiment, the medicine or preparation provided in the present application may further include a biodegradable polymer, for example, selected from collagen, chitosan, PLGA, PLA, PGA, PCL or a mixture thereof.

[0045] The medicine or preparation provided in the present application can be in the form of tablets, injections, liquid drops, sprays, gels, ointments, powders, lozenges, and any other dosage forms acceptable to veterinary clinics.

[0046] In a specific embodiment, the diphenylbutazone substance described in the present application is pimozide.

[0047] In some specific embodiments, the concentration of pimozide in the composition is 0.625-10 μM. For example, it can be 0.625 μM, 0.65 μM, 0.675 μM, 0.7 μM, 0.75 μM, 0.775 μM, 0.8 μM, 0.825 μM, 0.85 μM, 0.875 μM, 0.9 μM, 0.925 μM, 0.95 μM, 0.975 μM, 1 μM, 1.5 μM, 2 μM, 2.5 μM, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM, 5.5 μM, 6 μM, 6.5 μM, 7 μM, 7.5 μM, 8 μM, 8.5 μM, 9 μM, 9.5 μM, 10 μM.

[0048] In some specific embodiments, the dosage of pimozide is 20mg / kg-100mg / kg. For example, the dosage of pimozide can be 20mg / kg, 25mg / kg, 30mg / kg, 35mg / kg, 40mg / kg, 45mg / kg, 50mg / kg, 55mg / kg, 60mg / kg, 65mg / kg, 70mg / kg, 75mg / kg, 80mg / kg, 85mg / kg, 90mg / kg, 95mg / kg, 100mg / kg, preferably 50mg / kg-70mg / kg.

[0049] The present application also provides a method for preventing or treating African swine fever, which comprises administering to a subject an effective dose of a diphenylbutazone substance or the composition provided in the present application.

[0050] In a preferred embodiment, the diphenylbutazone substance is pimozide.

[0051] In a preferred embodiment, the African swine fever is an infectious disease caused by African swine fever virus.

[0052] The effective dose described in the present application refers to an amount sufficient to achieve the desired therapeutic result or to affect undesirable symptoms but generally insufficient to cause harmful side effects, and can be easily determined by those skilled in the art. In a specific embodiment, the effective dose is 20 mg / kg-100 mg / kg. In a preferred embodiment, the effective dose is 50 mg / kg-70 mg / kg.

[0053] The method provided in the present application includes oral, injection, buccal, inhalation, nasal, rectal, local skin or systemic administration. Specifically, the dosage and administration route to the subject vary according to the symptoms of the disease, the patient's condition, etc., and those skilled in the art can determine it based on actual conditions.

[0054] In the present application, endocytosis refers to endocytosis, also known as endocytosis, which is the process of transporting extracellular substances into cells through the deformation movement of the plasma membrane.

[0055] The technical method of the present application provides diphenylbutyridine-type substances such as pimozide, which have good virus inhibition effects. For example, they have significant inhibitory effects on ASFV gene copy number, ASFV titer, ASFV nucleic acid replication and protein synthesis. At the same time, in vitro cytotoxicity tests have found that pimozide has lower cytotoxicity, and therefore can be used as a potential drug for the treatment of ASF.

[0056] Example

[0057] The present application provides a general and / or specific description of the materials and test methods used in the experiments. In the following examples, unless otherwise specified, the reagents or instruments used without indicating the manufacturer are all conventional reagent products that can be obtained commercially.

[0058] The following experiments were conducted with biosafety permits and African swine fever laboratory activity permits:

[0059] The Biosafety Level 3 Laboratory (ABSL-3) of the China Veterinary Drug Administration has obtained a license for research on the pathogen of African swine fever and has registered it, meeting the national biosafety level requirements.

[0060] Unless otherwise specified, the operating methods in the experiment are all known in the art. The ASFV used in the following examples is genotype II ASFV (Zuo X, Peng G, Zhao J, et al. Infection of domestic pigs with a genotype II potent strain of ASFV causes cytokine storm and lymphocyte mass reduction. Front Immunol. 2024; 15: 1361531.

[0061] doi:10.3389 / fimmu.2024.1361531).

[0062] Main experimental instruments: constant temperature cell culture incubator, microplate reader.

[0063] Main technical scheme: First, the CCK-8 method (Cell Counting Kit-8) was used to detect the toxicity of pimozide to porcine alveolar macrophages (PAM) and determine its safe working concentration. Subsequently, the established ASFV infection model was used to evaluate the protective effect of pimozide on PAM cells infected with ASFV. The evaluation methods mainly included fluorescence quantitative PCR (qPCR) test, half red blood cell adsorption (HAD 50 ) tests, tests at different action stages, etc.

[0064] Example 1: CCK-8 method was used to detect the cytotoxicity of different concentrations of pimozide on PAM cells.

[0065] Cell Counting Kit-8 (CCK-8 for short) is a rapid, highly sensitive test kit based on WST-8 and widely used for cell proliferation and cytotoxicity detection. CCK-8 Cell Counting Kit, referred to as CCK-8 kit, is a rapid, highly sensitive, non-radioactive colorimetric test kit based on WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitro)-5(2,4-disulfonylbenzene)-2H-tetrazolyl monosodium salt) and widely used for cell proliferation and cytotoxicity detection. WST-8 can be reduced to a highly water-soluble orange-yellow formazan dye (formazan) by some dehydrogenases in mitochondria under the action of the electron coupling carrier 1-MethoxyPMS. The amount of formazan generated is proportional to the number of living cells, so the number of living cells can be indirectly determined to reflect cell proliferation and cytotoxicity. The absorbance value is measured at a wavelength of 450nm using an ELISA reader. The higher the absorbance value, the more formazan dye is generated and the more living cells there are. The CCK-8Solution in this kit is a ready-to-use reagent that can be directly added to the cell sample and tested after a certain incubation period without the need to pre-mix various components.

[0066] Main experimental methods:

[0067] 1.25×10 5 PAM / well was spread on a 96-well plate and adhered to the wall of a cell culture incubator at 37°C for more than 2 hours. 1640 containing 9% serum was used for gradient dilution, and the stock solution of pimozide was 10000μM. The dilutions were 2000μM, 1000μM, 500μM, 250μM, and 125μM, respectively. Each dilution was repeated 3 times, 20μL per well, and 80μL of 1640 containing 9% serum was added to make the total volume 200μL. The final concentration of pimozide was 200μM, 100μM, 50μM, 25μM, and 12.5μM. At the same time, a control group with cells but no pimozide and a blank group with no cells and pimozide were set up. Incubate in a cell culture incubator at 37°C for 72h. Discard the supernatant, add 10μL CCK-8 (protected from light) and 90ul serum-free 1640 to each well, and no bubbles are allowed. Incubate the cells at 37°C for 2 h. 450 Read the OD value of each well. Calculate the results: Cell survival rate = (experimental group - blank group) / (control group - blank group) × 100%.

[0068] The experimental results are as follows Figure 1 The results showed that at a concentration of 50 μM, pimozide had a survival rate of more than 90% for PAM cells and did not affect the proliferation of PAM cells.

[0069] Example 2: qPCR determination of the effect of pimozide on ASFV proliferation in PAM cells.

[0070] Main experimental methods:

[0071] 1.25×10 5 PAM / well was spread on a 96-well plate and adhered to the wall for more than 2 hours. Pimozide was diluted in 1640 gradients containing 9% serum, and the dilutions were 100μM, 50μM, 25μM, 12.5μM, 6.25μM, and 0μM, respectively. 10μl PAM cell supernatant was discarded, and each dilution was repeated 3 times, 20μL pimozide per well, and 90μL ASFV (MOI=0.16) was added to make the total volume 200μL. The final drug concentrations were 10μM, 5μM, 2.5μM, 1.25μM, 0.625μM, and 0μM. After standing in a 37℃ cell culture incubator for 72h, it was repeatedly frozen and thawed at -80℃ three times. ASFV was collected and nucleic acid was extracted. The copy number of ASFV was detected using p72 primer probe by qPCR, and the inhibition rate of pimozide on ASFV was calculated.

[0072] Table 1p72 primer names and corresponding sequences

[0073]

[0074] The test results are as follows Figure 2 As shown, the pimozide of the present invention has a significant inhibitory effect on ASFV at a concentration of 0.625 μM to 10 μM, and is dose-dependent.

[0075] Example 3: HAD 50 The effect of pimozide on ASFV titers in PAM cells was determined.

[0076] 1.25×10 5 PAM / well was spread on a 96-well plate and allowed to adhere to the wall for more than 2 hours. Pimozide was gradiently diluted using 1640 containing 9% serum, with the dilutions being 100μM, 50μM, 25μM, 12.5μM, 6.25μM, and 0μM, respectively. 10μl of PAM cell supernatant was discarded, and each dilution was repeated 3 times, with 20μL of pimozide per well, and 90μL ASFV (MOI=0.16) was added to make the total volume 200μL. The final drug concentrations were 10μM, 5μM, 2.5μM, 1.25μM, 0.625μM, and 0μM. After standing in a 37°C cell culture incubator for 72h, ASFV was collected by repeated freezing and thawing three times at -80°C. 1.25×10 5 PAM / well was plated in a 96-well plate and allowed to adhere to the plate for more than 2 hours. ASFV treated with each pimozide concentration was diluted 10-fold to 10 -8 , 100 μL per well, add 20 μL of 1% red blood cells at the same time, place in a 37°C cell culture incubator, observe red blood cell agglutination every day for 7 consecutive days. Calculate the half red blood cell adsorption dose (HAD) of ASFV50 ), the method is Reed-Muench method.

[0077] like Figure 3A As shown, the virus titer of pimozide of the present invention gradually decreases at a concentration of 0.625 μM to 10 μM, as shown in Figure 3B As shown in the figure, at different pimozide concentrations, the proliferation of African swine fever virus was observed by the number of rosette spots. As the dosage of pimozide increased, the number of rosette spots decreased. Therefore, pimozide has a significant inhibitory effect on the virus titer of ASFV infected PAM cells, and it shows a clear dose-dependency.

[0078] Example 4: qPCR determination of the effect of pimozide on different proliferation stages of ASFV in PAM cells.

[0079] 1.25×10 5 PAM / well was plated on a 96-well plate and allowed to adhere for more than 2 hours. Pimozide was serially diluted using 1640 containing 9% serum, with each dilution being 50 μM, 25 μM, and 0 μM. ASFV (MOI=0.16). Each dilution was repeated 3 times.

[0080] Direct killing: Investigate the direct killing effect of drugs. Take 20 μL of 50 μM, 25 μM, and 0 μM pimozide, then add 90 μL ASFV, incubate in a cell culture incubator at 37°C for 1 hour, and dilute 20 times to a concentration where pimozide has no inhibitory effect. Discard 10 μL of PAM cell supernatant and add 110 μL of the diluted mixture to PAM cells, with a total volume of 200 μL, and incubate in a cell culture incubator for 72 hours.

[0081] Pre (administration before cell entry): used to investigate the blocking effect of drugs or the effects on host factors. 20 μL of 50 μM, 25 μM, and 0 μM pimozide were added to PAM cells, and then 200 μL of 1640 with 9% serum was added, and incubated at 4°C for 2 hours. 1640 was washed 3 times, 90 μL ASFV was added with 110 μL of 1640 with 9% serum to PAM cells, and incubated at 4°C for 2 hours. 1640 was washed 3 times, 200 μL of 1640 with 9% serum was added to PAM cells, and incubated in a cell culture incubator at 37°C for 72 hours.

[0082] During (co-intracellular administration): discard 10 μL PAM cell supernatant, add 20 μL of 50 μM, 25 μM, 0 μM pimozide and 90 μL ASFV to PAM cells, and incubate in a 37°C cell culture incubator for 2 hours. Wash 1640 three times, add 200 μL of 9% serum 1640 to PAM cells, and incubate in a 37°C cell culture incubator for 72 hours.

[0083] Post-1 (administration after cell entry at 4°C): Investigate the inhibitory effect of drugs on viral nucleic acid replication and protein synthesis. 90μL ASFV was added to PAM cells, and then 200μL was made up with 1640 containing 9% serum, incubated at 4°C for 2h, and washed 3 times with 1640. 20μL of 50μM, 25μM, and 0μM pimozide were added to 3 groups of PAM cells, and then 200μL was made up with 1640 containing 9% serum, and incubated in a cell culture incubator for 72h.

[0084] Post-2 (administration after cell entry at 37°C): Investigate the inhibitory effect of drugs on viral nucleic acid replication and protein synthesis. 90μL ASFV was added to PAM cells, and then supplemented with 1640 with 9% serum to 200μL, incubated in a cell culture incubator at 37°C for 2h, and washed 3 times with 1640. 20μL of 50μM, 25μM, and 0μM pimozide were added to 3 groups of PAM cells, and then supplemented with 1640 with 9% serum to 200μL, and incubated in a cell culture incubator for 72h.

[0085] The cells incubated at different stages were frozen and thawed three times at -80°C after 72 hours, and ASFV was collected and nucleic acid was extracted. The copy number of ASFV was detected by qPCR using p72 primer probe, and the difference in ASFV copy number at different stages was compared.

[0086] The test results are as follows Figure 4 As shown, the pimozide of the present invention has no direct killing effect on ASFV. The copy number of the p72 gene is significantly reduced one day and two days after treatment, indicating that pimozide plays an inhibitory role in the nucleic acid replication and protein synthesis stages of the virus.

[0087] The foregoing merely illustrates the principles of the present application, and it should be understood that the scope of the present application is not intended to be limited to the exemplary aspects described herein, but should include all currently known and future developed equivalents. In addition, it should be noted that, without departing from the technical principles of the present application, several improvements and modifications may be made, and these improvements and modifications should also be considered as the scope of the present application.

Claims

1. The use of diphenylbutazone substances in the preparation of drugs or preparations for preventing or treating African swine fever.

2. The use according to claim 1, wherein: The diphenylbutazone-type substance is one or more than two of pimozide, fluspiride, fluphenazine and penfluridol.

3. The use according to claim 1, wherein: The diphenylbutazone substance is pimozide.

4. The use as claimed in claim 3, wherein an effective dose of pimozide is administered to a subject, wherein the effective dose is 50 mg / kg-70 mg / kg.

5. A composition for preventing or treating African swine fever, comprising diphenylbutazone substances and pharmaceutically acceptable excipients, and preferably also comprising other pharmaceutically active ingredients.

6. The composition according to claim 5, wherein The diphenylbutazone-type substance is one or more than two of pimozide, fluspiride, fluphenazine and penfluridol.

7. The composition according to claim 5, wherein the diphenylpiperidine substance is pimozide.

8. The composition according to claim 7, wherein The concentration of pimozide in the composition is 0.625-10 μM.

9. The composition according to claim 7, wherein The dosage of pimozide is 20 mg / kg-100 mg / kg.

Citation Information

Patent Citations

  • ATF6 inhibitors and uses thereof

    CN112313224A

  • Use of cyproheptadine hydrochloride compound in preparation of drug for preventing or treating african swine fever

    WO2022188898A2